Minimal residual disease

Wesley O. Greaves; Rajyalakshmi Luthra

doi:10.1007/978-1-4614-2170-2_19

Minimal residual disease

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Disease relapse remains a major problem in a significant proportion of patients treated for cancer. Molecular monitoring of minimal residual disease (MRD), usually using a real-time quantitative PCR-based approach, is an important tool for risk stratification and prognostication and can be used as a guide for optimizing clinical management in these patients. Most MRD monitoring is currently performed in patients with leukemia and lymphoma, while neuroblastoma is the only nonhematologic malignancy for which molecular testing for MRD is well established.

Original language	English (US)
Title of host publication	Modern Clinical Molecular Techniques
Publisher	Springer New York
Pages	281-293
Number of pages	13
ISBN (Electronic)	9781461421702
ISBN (Print)	1461421691, 9781461421696
DOIs	https://doi.org/10.1007/978-1-4614-2170-2_19
State	Published - Jul 1 2012
Externally published	Yes

Keywords

Acute promyelocytic leukemia
Leukemia
Lymphoma
Minimal residual disease
Real-time quantitative PCR

ASJC Scopus subject areas

General Medicine

Access to Document

10.1007/978-1-4614-2170-2_19

Cite this

@inbook{56a1c47aa29640f9ba3f3fe562024acd,

title = "Minimal residual disease",

abstract = "Disease relapse remains a major problem in a significant proportion of patients treated for cancer. Molecular monitoring of minimal residual disease (MRD), usually using a real-time quantitative PCR-based approach, is an important tool for risk stratification and prognostication and can be used as a guide for optimizing clinical management in these patients. Most MRD monitoring is currently performed in patients with leukemia and lymphoma, while neuroblastoma is the only nonhematologic malignancy for which molecular testing for MRD is well established.",

keywords = "Acute promyelocytic leukemia, Leukemia, Lymphoma, Minimal residual disease, Real-time quantitative PCR",

author = "Greaves, {Wesley O.} and Rajyalakshmi Luthra",

year = "2012",

month = jul,

day = "1",

doi = "10.1007/978-1-4614-2170-2_19",

language = "English (US)",

isbn = "1461421691",

pages = "281--293",

booktitle = "Modern Clinical Molecular Techniques",

publisher = "Springer New York",

}

TY - CHAP

T1 - Minimal residual disease

AU - Greaves, Wesley O.

AU - Luthra, Rajyalakshmi

PY - 2012/7/1

Y1 - 2012/7/1

N2 - Disease relapse remains a major problem in a significant proportion of patients treated for cancer. Molecular monitoring of minimal residual disease (MRD), usually using a real-time quantitative PCR-based approach, is an important tool for risk stratification and prognostication and can be used as a guide for optimizing clinical management in these patients. Most MRD monitoring is currently performed in patients with leukemia and lymphoma, while neuroblastoma is the only nonhematologic malignancy for which molecular testing for MRD is well established.

AB - Disease relapse remains a major problem in a significant proportion of patients treated for cancer. Molecular monitoring of minimal residual disease (MRD), usually using a real-time quantitative PCR-based approach, is an important tool for risk stratification and prognostication and can be used as a guide for optimizing clinical management in these patients. Most MRD monitoring is currently performed in patients with leukemia and lymphoma, while neuroblastoma is the only nonhematologic malignancy for which molecular testing for MRD is well established.

KW - Acute promyelocytic leukemia

KW - Leukemia

KW - Lymphoma

KW - Minimal residual disease

KW - Real-time quantitative PCR

UR - http://www.scopus.com/inward/record.url?scp=84949178017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949178017&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-2170-2_19

DO - 10.1007/978-1-4614-2170-2_19

M3 - Chapter

AN - SCOPUS:84949178017

SN - 1461421691

SN - 9781461421696

SP - 281

EP - 293

BT - Modern Clinical Molecular Techniques

PB - Springer New York

ER -

Minimal residual disease

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this